• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LU Shiping, JIN Liang, WU Jie. Clinical development of type 1 diabetes vaccine[J]. Journal of China Pharmaceutical University, 2014, 45(6): 625-632. DOI: 10.11665/j.issn.1000-5048.20140603
Citation: LU Shiping, JIN Liang, WU Jie. Clinical development of type 1 diabetes vaccine[J]. Journal of China Pharmaceutical University, 2014, 45(6): 625-632. DOI: 10.11665/j.issn.1000-5048.20140603
shu

Clinical development of type 1 diabetes vaccine

More Information
    Graphical Abstract
    • Abstract
  • Type 1 diabetes is an autoimmune disorder due to the pancreatic β cell damage with pancreatic inflammation and insulin resistance. For a long time, patients must inject insulin for treatment. Along with advanced development about type 1 diabetes, prevention and early diagnosis of diabetes become possible. This review summarizes the clinical and preclinical stagesintype 1 diabetes vaccine research as well as the recent researches about major biological targets, such as autoantigens or relevant monoclonal antibody and cytokines, respectively.
    • FullText(HTML)
    • References (55)
  • [1]
    Kilpatrick ES,Rigby AS,Atkin SL.Insulin resistance,the metabolic syndrome,and complication risk in type 1 diabetes “double diabetes” in the diabetes control an pancreatic islet autoantibodies as predictors of type 1d complications trial[J].Diabetes Care,2007,30(3):707-712.
    [2]
    Thorn LM,Forsblom C,Fagerudd J,et al.Metabolic syndrome in type 1 diabetes association with diabetic nephropathy and glycemic control(the FinnDiane study)[J].Diabetes Care,2005,28(8):2 019-2 024.
    [3]
    Gill GV,Woodward A,Casson IF,et al.Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes-the ‘dead in bed’ syndrome revisited[J].Diabetologia,2009,52(1):42-45.
    [4]
    Pipeleers D,Ling Z.Pancreatic beta cells in insulin-dependent diabetes[J].Diabetes Metab Res Rev,1992,8(3):209-227.
    [5]
    Diabetes Prevention Trial-Type 1 Diabetes Study Group.Effects of insulin in relatives of patients with type 1 diabetes mellitus[J].N Engl J Med,2002,346(22):1 685-1 691.
    [6]
    Staeva-Vieira T,Peakman M,Von Herrath M.Translational mini-review series on type 1 diabetes:immune-based therapeutic approaches for type 1 diabetes[J].Clin Exp Immunol,2007,148(1):17-31.
    [7]
    Lernmark Å, Larsson HE. Immune therapy in type 1 diabetes mellitus[J].Nat Rev Endocrinol,2013,9(2):92-103.
    [8]
    Jensen RA,Gilliam LK,Törn C,et al.Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15-to 35-year-old diabetic subjects[J].J Diabetes Complications,2007,21(4):205-213.
    [9]
    Orban T, Sosenko JM, Cuthbertson D, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the diabetes prevention trial- type 1[J].Diabetes Care,2009,32(12):2 269-2 274.
    [10]
    Barker JM,Barriga KJ,Yu L,et al.Prediction of autoantibody positivity and progression to type 1 diabetes:diabetes autoimmunity study in the young(DAISY)[J].J Clin Endocrinol Metab,2004,89(8):3 896-3 902.
    [11]
    Wenzlau JM,Juhl K,Yu L,et al.The cation efflux transporter ZnT8(Slc30A8)is a major autoantigen in human type 1 diabetes[J].Proc Natl Acad Sci U S A,2007,104(43):17 040-17 045.
    [12]
    Harrison LC.Vaccination against self to prevent autoimmune disease:the type 1 diabetes model[J].Immunol Cell Biol,2008,86(2):139-145.
    [13]
    Clemente-Casares X,Tsai S,Huang C,et al.Antigen-specific therapeutic approaches in type 1 diabetes[J].Cold Spring Harb Perspect Med,2012,2(2):a007773.
    [14]
    Davidson MB.Insulin analogs—is there a compelling case to use them?No[J]!Diabetes Care,2014,37(6):1 771-1 774.
    [15]
    Fourlanos S,Perry C,Gellert SA,et al.Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes[J].Diabetes,2011,60(4):1 237-1 245.
    [16]
    http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403122.htm.
    [17]
    Orban T,Farkas K,Jalahej H,et al.Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy[J].J Autoimmun,2010,34(4):408-415.
    [18]
    Garg SK,Buse JB,Skyler JS,et al.Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes[J].Diabetes Obes Metab,2014,16(11):1 065-1 069.
    [19]
    Ludvigsson J,Krisky D,Casas R,et al.GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus[J].N Engl J Med,2012,366(5):433-442.
    [20]
    Raz I,Elias D,Avron A,et al.β-Cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide(DiaPep277):a randomised,double-blind,phase II trial[J].Lancet,2001,358(9 295):1 749-1 753.
    [21]
    Schloot NC,Meierhoff G,Lengyel C,et al.Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1:two prospective,randomized,double-blind phase II trials[J].Diabetes Metab Res Rev,2007,23(4):276-285.
    [22]
    Fischer B,Elias D,Bretzel RG,et al.Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes-an update[J].Expert Opin Biol Ther,2010,10(2):265-272.
    [23]
    Raz I,Ziegler A G,Linn T,et al.Treatment of recent-onset type 1 diabetic patients with DiaPep277:results of a double-blind,placebo-controlled,randomized phase 3 trial[J].Diabetes Care,2014,37(5):1 392-1 400.
    [24]
    Liang J,Aihua Z,Yu W,et al.HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277 inducing anti-inflammatory immune response in NOD mice by nasal administration[J].Vaccine,2010,28(19):3 312-3 317.
    [25]
    Hinman RM,Smith MJ,Cambier JC.B cells and type 1 diabetes…in mice and men[J].Immunol Lett,2014.
    [26]
    Herold KC,Pescovitz MD,McGee P,et al.Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody(rituximab)therapy in type 1 diabetes[J].J Immunol,2011,187(4):1 998-2 005.
    [27]
    Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and β-cell function:two-year results[J].Diabetes Care,2014,37(2):453-459.
    [28]
    Hu C,Ding H,Zhang X,et al.Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes[J].Diabetes,2013,62(8):2 849-2 858.
    [29]
    Sarikonda G,Sachithanantham S,Manenkova Y,et al.Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin:immunologic effects and efficacy in NOD mice[J].PLoS One,2013,8(2):e54712.
    [30]
    Herold KC,Pescovitz MD,McGee P,et al.Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody(rituximab)therapy in type 1 diabetes[J].J Immunol,2011,187(4):1 998-2 005.
    [31]
    Penaranda C,Tang Q,Bluestone JA.Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells[J].J Immunol,2011,187(4):2 015-2 022.
    [32]
    Hagopian W,Ferry RJ,Sherry N,et al.Teplizumab preserves C-peptide in recent-onset type 1 diabetes two-year results from the randomized,placebo-controlled Protégé trial[J].Diabetes,2013,62(11):3 901-3 908.
    [33]
    Daifotis AG,Koenig S,Chatenoud L,et al.Anti-CD3 clinical trials in type 1 diabetes mellitus[J].Clin Immunol,2013,149(3):268-278.
    [34]
    Keymeulen B,Walter M,Mathieu C,et al.Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass[J].Diabetologia,2010,53(4):614-623.
    [35]
    Shao S,He F,Yang Y,et al.B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in type 1 diabetes[J].Cell Immunol,2012,280(1):16-21.
    [36]
    Grishman EK,White PC,Savani RC.Toll-like receptors,the NLRP3 inflammasome,and interleukin-1β in the development and progression of type 1 diabetes[J].Pediatr Res,2012(71):626-632.
    [37]
    Moran A,Bundy B,Becker DJ,et al.Interleukin-1 antagonism in type 1 diabetes of recent onset:two multicentre,randomised,double-blind,placebo-controlled trials[J].Lancet,2013,381(9 881):1 905-1 915.
    [38]
    Ablamunits V,Henegariu O,Hansen JB,et al.Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 Blockade evidence of improved immune regulation[J].Diabetes,2012,61(1):145-154.
    [39]
    Long SA,Buckner JH,Greenbaum CJ.IL-2 therapy in type 1 diabetes:“trials” and tribulations[J].Clin Immunol,2013,149(3):324-331.
    [40]
    Grinberg-Bleyer Y,Baeyens A,You S,et al.IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells[J].J Exp Med,2010,207(9):1 871-1 878.
    [41]
    Long SA.Rapamycin plus IL 2 combination therapy in subjects with T1D results in a sustained increase in IL 2 responsiveness and a transient decrease in C-peptide levels[C].Proceedings of the 71st Scientific Sessions American Diabetes Association Annual Meeting,2011:24-28.
    [42]
    Waldron-Lynch F,Kareclas P,Irons K,et al.Rationale and study design of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes(DILT1D):a non-randomised,open label,adaptive dose finding trial[J].BMJ Open,2014,4(6):e005559.
    [43]
    Padgett LE,Broniowska KA,Hansen PA,et al.The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis[J].Ann N Y Acad Sci,2013,1 281(1):16-35.
    [44]
    Mastrandrea L,Yu J,Behrens T,et al.Etanercept treatment in children with new-onset type 1 diabetes pilot randomized,placebo-controlled,double-blind study[J].Diabetes Care,2009,32(7):1 244-1 249.
    [45]
    Faustman DL,Wang L,Okubo Y,et al.Proof-of-concept,randomized,controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes[J].PLoS One,2012,7(8):e41756.
    [46]
    Lind M,Jendle J,Torffvit O,et al.Glucagon-like peptide 1(GLP-1)analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction[J].Prim Care Diabetes,2012,6(1):41-46.
    [47]
    Kielgast U,Krarup T,Holst JJ,et al.Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function[J].Diabetes Care,2011,34(7):1 463-1 468.
    [48]
    Garg SK,Moser EG,Bode BW,et al.Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes:investigator-initiated,double-blind,randomized,placebo-controlled trial[J].Endocr Pract,2013,19(1):19-28.
    [49]
    Ellis SL,Moser EG,Snell-Bergeon JK,et al.Effect of sitagliptin on glucose control in adult patients with type 1 diabetes:a pilot,double-blind,randomized,crossover trial[J].Diabet Med,2011,28(10):1 176-1 181.
    [50]
    Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression[J].Am J Transplant,2011,11(1):22-33.
    [51]
    Weinberg A,Boulware D,Dighero B,et al.Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes[J].Vaccine,2013,31(42):4 791-4 794.
    [52]
    Orban T,Bundy B,Becker DJ,et al.Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes:a randomised,double-blind,placebo-controlled trial[J].Lancet,2011,378(9 789):412-419.
    [53]
    Park MH,Igarashi K.Polyamines and their metabolites as diagnostic markers of human diseases[J].Biomol Ther,2013,21(1):1-9.
    [54]
    Tersey SA,Colvin SC,Maier B,et al.Protective effects of polyamine depletion in mouse models of type 1 diabetes:implications for therapy[J].Amino acids,2014,46(3):633-642.
    [55]
    Wu J,Liu XR,Yang X,et al.Hypoglycemic effect of Lactococcus lactis vaccine containing HSP65-6P277 on streptozotocin-induced type 1 diabetic mice[J].J China Pharm Univ(中国药科大学学报),2014, 45(1):106-110.
    • Related Articles

  • Related Articles

    [1]LU Ningshu, JI Tao, LU Yinglan, XU Xiyuan, GU Xiaochen, DING Yang. Drug delivery strategies and clinical research progress for encephalopathy[J]. Journal of China Pharmaceutical University, 2024, 55(5): 577-589. DOI: 10.11665/j.issn.1000-5048.2024063001
    [2]WANG Chen, ZHANG Zhengping, LI Yinchun. Development strategy and clinical research progress of universal chimeric antigen receptor T-cell drugs[J]. Journal of China Pharmaceutical University, 2023, 54(2): 141-149. DOI: 10.11665/j.issn.1000-5048.20211125001
    [3]XIA Ying, GUO Hongli, HU Yahui, CHEN Feng. Therapeutic drug monitoring for monoclonal antibody：progress in the application of LC-MS/MS technique[J]. Journal of China Pharmaceutical University, 2021, 52(1): 122-128. DOI: 10.11665/j.issn.1000-5048.20210117
    [4]YU Tianhong, Siva Bharath MERUGU, Hema NEGI, SUN Songxuan, DING Yunhe, WU Zhenghua, LI Dawei. AGR2-blocking antibody 18A4 inhibits cellular tumorigenic properties induced by extracellular AGR2[J]. Journal of China Pharmaceutical University, 2018, 49(2): 238-246. DOI: 10.11665/j.issn.1000-5048.20180215
    [5]YIN Kunpeng, ZHENG Hao, XIE Binxin, LI Ping, ZHANG Lei, FAN Yong, ZHU Wei, QI Lianwen. Clinical metabolomics in diagnosis and therapy of coronary artery disease[J]. Journal of China Pharmaceutical University, 2017, 48(6): 629-634. DOI: 10.11665/j.issn.1000-5048.20170601
    [6]WANG Chen, ZHANG Zhewen, LI Yingchun, ZHANG Xiquan, ZHAO Wei. Advances of the effects of antibody heterogeneity on the function and metabolism of monoclonal antibody drugs[J]. Journal of China Pharmaceutical University, 2017, 48(5): 614-621. DOI: 10.11665/j.issn.1000-5048.20170518
    [7]PAN Jiajia, JIA Xiaoqing, HUANG Gang, ZHANG Yubin. PD-1/PD-Ls signaling pathway and the application of anti-PD-1/PD-Ls antibodies in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(1): 9-18. DOI: 10.11665/j.issn.1000-5048.20160102
    [8]LUO Kaiming, ZHAO Hu, GAO Xiangdong. Preparation of a monoclonal antibody against hyaluronic acid and its application in immunoassay[J]. Journal of China Pharmaceutical University, 2015, 46(6): 740-744. DOI: 10.11665/j.issn.1000-5048.20150618
    [9]HE Hua, ZHANG Xue, WANG Yuhao, LIU Xiaoquan. Advances in pharmacokinetic and pharmacodynamic modeling of monoclonal antibody[J]. Journal of China Pharmaceutical University, 2015, 46(3): 279-288. DOI: 10.11665/j.issn.1000-5048.20150304
    [10]Preparation and Preliminary Identification of Monoclonal Antibody Against Hepatitis A Virus[J]. Journal of China Pharmaceutical University, 2002, (2): 75-77.

Catalog

    Get Citation
    PDF
    XML
    Article views (1326) PDF downloads (1095) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：415019

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return